Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics

What caused the Titan sub implosion? Why did Meta violate privacy laws? How did Trump’s tariffs impact US-India trade? Why are Tesla’s European sales declining? What’s behind Rivian’s bigger financial losses? How will Trump’s Fed chair picks affect markets? Why did Snap’s revenue growth slow?

Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics

benzinga.com/news/fda/25/07/46700328/sephience-gets-fda-approval-now-a-key-revenue-driver-for-ptc-therapeutics

The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.’s (NASDAQ:PTCT) SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).
PTCT stock is on the move, climbing higher. Check the latest price here.
PKU is a rare, inherited disorder…

This story appeared on benzinga.com, 2025-07-29 17:58:58.